The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer

Kelvin K H Bao; Leone Sutanto; Shirley S W Tse; Ka Man Cheung; Jeffrey C H Chan

doi:10.1001/jamanetworkopen.2021.33132

The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer

JAMA Netw Open. 2021 Nov 1;4(11):e2133132. doi: 10.1001/jamanetworkopen.2021.33132.

Authors

Kelvin K H Bao¹, Leone Sutanto¹, Shirley S W Tse¹, Ka Man Cheung¹, Jeffrey C H Chan¹

Affiliation

¹ Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong.

Abstract

This cohort study investigates the association between low levels of ERBB2 expression and progression-free survival among patients with HR+/ERBB2− metastatic breast cancer treated with CDK4/6 inhibitors.

MeSH terms

Adult
Breast Neoplasms / metabolism
Breast Neoplasms / pathology*
Cohort Studies
Cyclin-Dependent Kinase 4 / metabolism*
Cyclin-Dependent Kinase 6 / metabolism*
Disease Progression
Female
Hong Kong
Humans
Middle Aged
Receptor, ErbB-2 / metabolism*

Substances

ERBB2 protein, human
Receptor, ErbB-2
CDK4 protein, human
CDK6 protein, human
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6